# Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

> **NCT06617455** · PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Breast Ductal Carcinoma In Situ
- Localized Breast Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Fezolinetant
- **DRUG:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT06617455
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-10-31
- **Primary completion:** 2025-10-22
- **Final completion:** 2025-11-21
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Lack of Patient Interest
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06617455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06617455, "Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06617455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*